NRx Pharmaceuticals
NRx Pharmaceuticals is a clinical-stage pharmaceutical company developing therapeutics for the treatment of central nervous system disorders and pulmonary diseases. It addresses life-threatening diseases that often go untreated by researching, developing, and scaling solutions to help people who most desperately need them. The company has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure, and is also developing NRX-100/101 which is the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior. In July 2021, the Government of Israel awarded NRx the exclusive worldwide right to develop and market the BriLifeR COVID vaccine developed by the Israel Institute for Biological Research.
Tech Stack (25 technologies)
Frequently Asked Questions
What technologies does NRx Pharmaceuticals use?+
NRx Pharmaceuticals uses 25 technologies including cdnjs, Google Analytics, Google Tag Manager.
What industry is NRx Pharmaceuticals in?+
NRx Pharmaceuticals operates in the Biopharma industry.
Where is NRx Pharmaceuticals based?+
NRx Pharmaceuticals is headquartered in United States.
Explore More
Need this data at scale?
Get ready-to-use datasets: companies, technologies, and tech adoption signals across 3M+ websites.
Browse DatasetsData last updated: June 2026